Introductory Offer on New Products - Antibodies for Exosomal Markers CD9, CD81. Free Shipping in Taiwan.

RELIANCE BIOSCIENCES delivers molecular diagnostics
via exosomes for diagnostic and assessment of
neurodegenerative diseases and unmet clinical needs.

Exosomes are nanoparticles secreted from disease-specific cells and provide personalized and actionable disease insights. Our proprietary immunoassay technology enables high sensitivity exosomal protein detection using blood.

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset
Exosomes from blood for risk assessment of Alzheimer's Disease | Reliance Biosciences

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset

UNMET NEEDS

1
million
Americans living with Alzheimer’s in 2019
1
million
Americans estimated to have Alzheimer’s by 2050
1
million
People worldwide living with Alzheimer’s in 2019

our PIPELINE

Diagnostics via exosome

PARTNERSHIP

We are seeking partnership with diagnostic labs in laboratory-developed test (LDT) of early Alzheimer’s disease in Japan and USA.

TECHNICAL MILESTONES

Seed grant of USD 1.1 million_Reliance Biosciences_Molecular diagnostics via exosomes

1. Seed grant

Seed grant of USD 1.1 million successfully executed.

Licensing_National Taiwan University_Reliance Biosciences_Molecular diagnostics via exosomes

2. Licensing

Exclusively licensed technology from the National Taiwan University.

Prototypes_immunoassay_Reliance Biosciences_molecular diagnostics via exosomes

3. Prototypes

RExo-system completed: (a) RExo-analyzer: multiplex sample preparation & analysis and (b) RExo-assay: multiplex fluidic assay

Agreement_Alzheimer's_Reliance Biosciences

4. Executed Agreement

Fully executed agreement with an Australian Alzheimer organization with 8,500 contact-patient-year samples available for fast-track study on AD, with PET scan data as control.

5. MTA executed

MTA fully executed with Harvard Med School/MGH with 500 samples for early assessment of lung cancer.

6. NDA executed

Multiple NDAs fully executed with pharmas and organizations towards clinical development.